It's very interesting indeed. I'm not sure how accurate my calculation is but if it's correct then a similar rise in cap for biota would put it at $12 a share!
Hopefully we see some sort of announcement on Wednesday regarding a possible full Nasdaq listing. They have more than enough cash to sustain a proper nasdaq listing, why not do it? Letting your stock price trade well below value will only attract opportunistic takeover bids.
Time will tell how much value Laninamivir will add to Biota's market cap. I'm guessing that a license deal will give some comfort and we know major pharma are currently doing due diligence on the drug. Fantastic phase III results can only help.
This is a mega-blockbuster market and Laninamivir has the potential to grab a decent stake. Relenza's 7% royalty is already bringing in massive cashflow and LANI has the potential to attract a far higher number... once this is all cemented then the analysts can plug in the numbers into a spreadsheet... crossing my fingers here that management can lock in a "deal of the decade" in aussie biotech.
BTA Price at posting:
$2.08 Sentiment: Buy Disclosure: Held
